GenScript's MonoRab™ technology generates a large number of high quality rabbit monoclonal antibodies for any application. Our proprietary hetero-hybridoma methodology includes an optimized fusion partner to improve overall fusion efficiency while utilizing the rabbit's natural ability to generate high specificity, high affinity mAb's against a wide range of difficult targets such as small molecules, Ab drugs, and even antigens that are non-immunogenic in mice.
Delivery of up to 10 different mAb sequences
Highly cost effective with clone number guarantees
Expert level downstream rAb expression services
MonoRab™ is a full-scale service which combines GenScript’s expertise in peptide generation, molecular biology, recombinant protein expression, and antibody discovery. Through GenScript’s novel antibody generation technology, MonoRab™ is able to produce large scales of recombinant antibodies while maintaining native antibody chains at a highly competitive price.
|Antigen Design||GenScript-generated or customer-supplied protein or peptide with conjugation||1-6 Wks||GenScript-generated peptide (2 mg) or protein (0.2mg)|
|Immunization||Immunization of 4 New Zealand White Rabbits followed by pAb screening||8-10 Wks||Antiserum report & 0.1 mg purified pAb/rabbit|
|Cell Fusion & Screening||One electrofusion from customer-chosen rabbit followed by ELISA screening to identify positive clones||2-3 Wks||Positive clones report|
|Sequencing & Small Scale rAb Expression||Antibody sequencing of 10 positive clones followed by small scale rAb expression||4-6 Wks||Sequence report & rAb supernatants or 0.1mg purified rAb for up to 10 clones|
|Large Scale Expression||Customer chosen sequences used for large scale rAb expression (0.1 mg-10 mg)||4-6 Wks||Sequencing report & purified antibody|
Due to the rabbits superior immune system, they can generate antibodies with higher specificity, sensitivity, affinity, and diversity than those generated in more commonly used model species.
Non-rabbit mAbs often fail to detect difficult antigens (Ags) such as small molecules, Ags with highly similar epitopes, post-transcriptionally-modified Ags, and Ags with no immunogenicity in mice. They also tend to require stringent optimization protocols in order to work in certain applications, possibly affecting the overall effectiveness of the experiment and interpretation of the results.
In Vitro Diagnostics: A variety of In Vitro diagnostic (IVD) assays, such as IHC, ELISA, and radio immunoassays (RI) are based on the principles of antigen-antibody binding. Given the critical role these assays play in patient and animal care, it is extremely important that IVD assays are carried out using the highest sensitivity and affinity mAbs available.
In Vivo Imaging: Visualization of mAbs can be accomplished through numerous means; however, the most common method is through labelling of mAbs with radioactive or fluorescent molecules to help track them in the body and aid in quantifying the results.
In Vitro Diagnostics (IVD)
In Vivo Imaging
Anti-Idiotype Antibodies: Pharmacokinetic (PK) assays are used to measure the absorption and excretion rates, distribution, and half-life of candidate small molecules or mAb therapeutics. Results from these assays help identify the optimal dose and toxicity risks of a therapeutic molecule. Therefore anti-idiotype antibodies need to be sensitive enough to capture trace amounts of their antibody target in free, bound, and total forms in biological fluid samples.
mAb therapeutics: The high specificity and sensitivity of an antibody towards its target antigen reduces both safety and toxicity concerns: highly specific antibodies avoid off-target binding and hence, offer safety; highly sensitive antibodies require low dosage administration and hence, cause a minimum level of toxicity.
CAR-T mAb Based Therapeutic
Feature in “The Scientist”
Introduction to GenScript’s Premier Rabbit mAb Generation platform
Rabbit Monoclonal Antibodies in Tissue Diagnostics
A The cross reactivity rate of GenScript produced anti-Ractopamine (small molecule) rabbit mAb is 0.0304%, showing low cross reactivity rates with similar compounds.
B GenScript produced anti-idiotype rabbit mAb 90G12F8 binds with Pembrolizumab (mAb drug) with an EC50 of 5.001 ng/ml as shown via ELISA.
C Genscript produced N-Terminal anti-flag-tag rabbit (section 1) mAb shows higher specificity and affinity than those produced in mouse (section 2) as shown via western blot.
D GenScript produced anti-idiotype rabbit mAb 90G12F8 has a KD valu e of 2.3x10 -12 M against the antibody drug (Pembrolizumab) as shown via ELISA.